tbResList Print — Maqui MBE, Maqui berry

Filters: qv=524, qv2=%, rfv=%

Product

Maqui MBE, Maqui berry
Description:
<p><b>Maqui Berry (Aristotelia chilensis)</b> — A dark-purple berry native to Chile and Argentina, exceptionally rich in anthocyanin polyphenols, particularly delphinidin and cyanidin glycosides. It is classified as a food source and botanical nutraceutical rather than an isolated therapeutic compound. Common abbreviations include MBE (maqui berry extract). Its principal constituents include delphinidin-3,5-diglucoside, delphinidin-3-sambubioside-5-glucoside, other delphinidin and cyanidin glycosides, and smaller quantities of flavonols and phenolic acids. Commercial preparations include whole-fruit powders, freeze-dried berry powders, and standardized anthocyanin-rich extracts such as Delphinol and MaquiBright. Research focuses on oxidative stress, inflammation, intestinal glucose transport, ocular surface health, and preliminary anticancer activity.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li><b>Antioxidant and redox modulation:</b> Anthocyanins and phenolic metabolites exhibit radical-scavenging activity and can reduce oxidative damage and lipid peroxidation. NRF2-associated cytoprotective signaling is a proposed secondary mechanism, with tissue- and model-dependent evidence.</li>
<li><b>Anti-inflammatory signaling:</b> ↓ iNOS, COX-2, nitric oxide production, and inflammatory mediator activity in stimulated macrophage and inflammatory models; NF-κB and NLRP3 modulation may contribute in specific experimental systems.</li>
<li><b>Intestinal glucose absorption:</b> ↓ SGLT1-mediated glucose transport, contributing to reduced postprandial glucose excursions in small human studies of standardized delphinidin-rich extracts.</li>
<li><b>Ocular surface protection:</b> Improved lacrimal secretion and reduced ocular surface inflammation, supported by small randomized clinical trials of standardized maqui extracts.</li>
<li><b>Anticancer apoptosis:</b> ↑ apoptosis and ↓ cancer cell viability in experimental models, particularly Ishikawa endometrial carcinoma cells exposed to concentrated hydroethanolic extracts.</li>
<li><b>Cancer invasion:</b> ↓ invasive capacity in endometrial carcinoma cell culture; effects on migration and other tumor phenotypes are model-dependent.</li>
<li><b>Cardiometabolic oxidative stress:</b> ↓ oxidized LDL and selected lipid-peroxidation biomarkers in some human studies; long-term clinical benefits remain uncertain.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Native anthocyanins have limited oral systemic bioavailability and undergo intestinal and microbial metabolism. After a 1000 mg single oral dose of standardized extract, delphinidin-3-glucoside peaked at approximately 1 hour and cyanidin-3-sambubioside at approximately 2 hours, approaching baseline within 8 hours. Phenolic metabolites, including gallic acid and protocatechuic acid, may contribute to biological effects. Exposure varies substantially between whole-fruit powders and standardized extracts.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Anticancer experiments commonly require concentrations substantially exceeding realistic circulating levels following oral consumption. An Ishikawa endometrial cancer study reported an extract EC50 of approximately 472 µg/mL, whereas circulating intact anthocyanins after oral dosing were measured in the nanomolar range. Direct systemic anticancer effects therefore remain pharmacokinetically unsubstantiated. Intestinal mechanisms are more plausible because gastrointestinal tissues experience higher local concentrations.</p>

<p><b>Clinical evidence status:</b> Small human RCTs support preliminary improvements in dry-eye symptoms, tear secretion, and acute postprandial glucose regulation with selected standardized extracts. Human studies also report changes in oxidative stress biomarkers, but results are heterogeneous. Cancer evidence remains preclinical; no established cancer treatment, prevention indication, or proven chemotherapy adjunct benefit exists. Maqui supplements are not approved anticancer therapies.</p>

<p><b>Safety / limitations:</b> Short-duration human studies generally report good tolerability, but long-term safety, pregnancy safety, and interaction data remain limited. Glucose-lowering effects warrant caution when combined with antidiabetic medication. Extract potency, anthocyanin standardization, fruit processing, and product formulation substantially affect reproducibility. Evidence from purified delphinidin or other berry anthocyanins should not automatically be attributed to whole maqui berry.</p>



<h3>Maqui Berry — Mechanistic Effects</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Oxidative Stress / ROS</td>
<td>↔ (context-dependent)</td>
<td>↓ ROS and lipid peroxidation</td>
<td>R/G</td>
<td>Antioxidant protection</td>
<td>Strong chemical antioxidant activity and experimental redox effects. Cancer-selective ROS modulation has not been demonstrated for oral maqui.</td>
</tr>
<tr>
<td>2</td>
<td>Inflammation / iNOS / COX-2</td>
<td>↓ inflammatory signaling (model-dependent)</td>
<td>↓ iNOS, COX-2 and NO in activated macrophages</td>
<td>G</td>
<td>Anti-inflammatory modulation</td>
<td>Demonstrated using maqui fractions and constituent mixtures in inflammatory cell models.</td>
</tr>
<tr>
<td>3</td>
<td>SGLT1 / Intestinal Glucose Transport</td>
<td>Not established</td>
<td>↓ intestinal glucose transport</td>
<td>P/R</td>
<td>Reduced postprandial glycemia</td>
<td>Mechanistic intestinal evidence and small human trials using standardized Delphinol extract.</td>
</tr>
<tr>
<td>4</td>
<td>Apoptosis / Cell Viability</td>
<td>↑ apoptosis; ↓ viability</td>
<td>↔ (insufficient comparative data)</td>
<td>G</td>
<td>Antiproliferative effect</td>
<td>Ishikawa endometrial carcinoma cells; extract EC50 approximately 472 µg/mL (high concentration only). No demonstrated in-vivo cancer efficacy.</td>
</tr>
<tr>
<td>5</td>
<td>Invasion / Metastatic Phenotype</td>
<td>↓ invasion</td>
<td>Not established</td>
<td>G</td>
<td>Reduced invasive capacity</td>
<td>Observed in Ishikawa cells; migration was not significantly reduced. Clinical metastasis prevention is unproven.</td>
</tr>
<tr>
<td>6</td>
<td>NF-κB / NLRP3 Inflammatory Signaling</td>
<td>↔ (not established for tumor models)</td>
<td>↓ inflammatory activation (model-dependent)</td>
<td>G</td>
<td>Inflammatory signal attenuation</td>
<td>Supported primarily by experimental inflammatory disease models; effects vary by cell type and exposure.</td>
</tr>
<tr>
<td>7</td>
<td>NRF2 / Antioxidant Response</td>
<td>↔ (context-dependent)</td>
<td>↑ cytoprotective signaling (model-dependent)</td>
<td>G</td>
<td>Secondary redox adaptation</td>
<td>Proposed contributor to antioxidant effects; not sufficiently established as the primary mechanism of whole maqui berry.</td>
</tr>
<tr>
<td>8</td>
<td>Lacrimal Function / Ocular Inflammation</td>
<td>Not applicable</td>
<td>↑ tear secretion; ↓ inflammatory cytokines</td>
<td>G</td>
<td>Improved ocular surface homeostasis</td>
<td>Small randomized human trials report improvements in dry-eye parameters after several weeks of supplementation.</td>
</tr>
<tr>
<td>9</td>
<td>Oxidized LDL / Lipid Peroxidation</td>
<td>Not established</td>
<td>↓ oxidative damage markers</td>
<td>G</td>
<td>Cardiometabolic antioxidant effect</td>
<td>Preliminary human biomarker findings; clinical cardiovascular event reduction remains unproven.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>High in-vitro extract exposure required</td>
<td>Low circulating native anthocyanins</td>
<td>P/R/G</td>
<td>Limited systemic anticancer plausibility</td>
<td>Oral absorption, rapid metabolism, extract heterogeneity, absence of oncology trials, and insufficient tumor exposure data limit clinical translation.</td>
</tr>
</tbody>
</table>
<p>TSF: P: 0–30 min R: 30 min–3 hr G: &gt;3 hr</p>




Pathway results for Effect on Cancer / Diseased Cells

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   iNOS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,  

Migration(tgid=13) ⓘ

TumCI↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   Inflam↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   lipid-P↓, 1,   ROS↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 7

Research papers

Year Title Authors PMID Link Flag
2026Clinical Evidence on the Health Effects of Aristotelia chilensis (Maqui Berry) Supplementation: A Systematic Review of Human TrialsPatricio Arce-JohnsonPMC13295803https://pmc.ncbi.nlm.nih.gov/articles/PMC13295803/0
2021Hydroethanolic Extracts of the Aristotelia Chilensis (Maqui) Berry Reduces Cellular Viability and Invasiveness in the Endometrial Cancer Cell Line IshikawaJavier MenaPMC8113921https://pmc.ncbi.nlm.nih.gov/articles/PMC8113921/0
2018Antioxidant and anti-inflammatory effects of extracts from Maqui berry Aristotelia chilensis in human colon cancer cellsCarlos L. Céspedes-Acuña—https://journals.sagepub.com/doi/10.3233/JBR-1803560